CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
A Phase 1 clinical trial of CTX310, an investigational CRISPR-Cas9 gene-editing therapy, safely reduced LDL cholesterol by nearly 50% and triglycerides by about 55% in participants with difficult-to-treat lipid disorders. The treatment represents a potential breakthrough for patients who struggle with medication adherence and could transform cardiovascular disease prevention if confirmed in larger studies.
The trial tested CTX310 as a one-time intravenous infusion that uses lipid nanoparticles to deliver the CRISPR editing mechanism to the liver, where it permanently switches off the ANGPTL3 gene. This approach mimics natural mutations found in people who have lifelong low cholesterol and triglyceride levels without apparent harmful effects. Cholesterol and triglyceride levels began dropping within two weeks after treatment and remained reduced for at least 60 days of follow-up, with reductions of up to 60% at the highest dose.
According to study author Dr. Luke J. Laffin, a preventive cardiologist at the Cleveland Clinic, "This is really unprecedented. A single treatment that simultaneously lowered LDL cholesterol and triglycerides. If confirmed in larger trials, this one-and-done approach could transform care for people with lifelong lipid disorders and dramatically reduce cardiovascular risk." The therapy marks the first treatment to achieve large reductions in both LDL cholesterol and triglycerides simultaneously, particularly important for patients with mixed lipid disorders who often have elevations in both.
The safety profile appeared favorable, with three participants experiencing minor infusion-related reactions that resolved with medication, and one participant with pre-existing elevated liver enzymes had a temporary further rise that normalized without treatment. No long-term or serious safety concerns were observed, though participants will be monitored for 15 years as recommended by the U.S. Food and Drug Administration for all CRISPR-based therapies. The American Heart Association's cholesterol education resources emphasize the importance of managing both cholesterol types for cardiovascular health.
Study co-author Dr. Steven E. Nissen highlighted the adherence challenges with current cholesterol medications, noting that "Many patients stop taking their cholesterol medications within the first year. The possibility of a one-time treatment with lasting effects could be a major clinical advance." The trial included 15 adults with elevated lipid levels despite maximum tolerated therapies, including patients with familial hypercholesterolemia and severe hypertriglyceridemia. The research was conducted at six sites in Australia, New Zealand and the United Kingdom between June 2024 and August 2025.
High cholesterol affects approximately 86.4 million U.S. adults and remains a major risk factor for heart disease and stroke, the leading causes of death worldwide. The American Heart Association recently launched the Lower Your LDL Cholesterol Now Initiative, a three-year national effort to improve cholesterol management. While the initial results are promising, researchers caution that the small, primarily male participant group and limited follow-up period require confirmation in larger, more diverse Phase 2 studies planned for late 2025 or early 2026.